This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): CC-930, PS873266, JNK 930
Description: CC-930 is a Jun N-terminal Kinase (JNK) Inhibitor. The JNK gene regulation pathway has been shown to play an essential role in the onset and progression of a variety of diseases that involve inflammation, cell death, ischemia/reperfusion injury and cellular proliferation.
Deal Structure: Under a collaboration initiated in 2003, Pharmacopeia scientists identified lead compounds acting at Celgene's inflammation-related kinase target. Celgene is solely responsible for the funding and management of development and commercialization of this drug candidate. Pharmacopeia receives an annual license fee from Celgene for this program and is eligible to receive milestone payments if the program advances further in clinical trials. Pharmacopeia will also receive royalties on sales of any resulting therapeutic products incorporating compounds derived from the program.
In September 2008, Ligand Pharmaceuticals announced that it entered into a definitive merger agreement to acquire Pharmacopeia in a deal valued up to $70 million.
In December 2008, Ligand Pharmaceuticals announced that it has completed the acquisition of Pharmacopeia.
Partners: Ligand Pharmaceuticals, Inc.
Additional information available to subscribers only: